Navigation Links
Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes
Date:8/27/2009

TEL AVIV, Israel, August 27 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd. ("EMI" or the "Company") (NASDAQ: EMITF), announced today, in accordance with Section 4 of the "Terms Behind the Page" of Series B Notes of the Company, that the interest rate borne by Series B Notes for the interest period beginning on August 21, 2009 and ending on February 20, 2010 is 1.723125%.

About Elbit Imaging Ltd.

The Activities of Elbit Imaging Ltd. are divided into the following principal fields: (i) Shopping and Entertainment Centers - Initiation, construction, operation, management and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India; (ii) Hotels - Hotel ownership, operation, management and sale, primarily in major European cities; (iii) Image Guided Treatment - Investments in the research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment; (vi) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real projects, predominantly residential, located in Eastern Europe and in India; and (v) Other Activities - (a) The distribution and marketing of fashion apparel and accessories in Israel; (b) venture capital investments; and (c) investments in hospitals, and farm and dairy plants in India, which are in preliminary stages.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2008, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2008, under the caption "Risk Factors."

    For Further Information:

    Company Contact
    Shimon Yitzhaki, President
    Elbit Imaging Ltd.
    Tel:+972-3-608-6000
    syitzhaki@elbitimaging.com

    Dudi Machluf, CFO
    Elbit Imaging Ltd.
    Tel:+972-3-608-6024
    dudim@elbitimaging.com

    Investor Contact
    Mor Dagan
    Investor Relations
    Tel:+972-3-516-7620
    mor@km-ir.co.il


'/>"/>
SOURCE Elbit Imaging Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
2. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
3. Elbit Medical Imaging Ltd. Announces Results of Its Annual General Meeting
4. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
5. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
6. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
7. Imaging Diagnostic Systems Generates Cash From Building Sale
8. Imaging quantum entanglement
9. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
10. Imaging Diagnostic Systems Expands Key Patent Coverage
11. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... /PRNewswire -- WuXi AppTec, a leading global pharmaceutical, ... platform, today announced that it has acquired HD ... discovery contract research organization (CRO). After completion of ... of WuXi, and will continue to focus on ... The acquisition will further strengthen WuXi,s R&D capability ...
(Date:1/19/2017)... 19, 2017  ArmaGen, Inc., today announced that ... as chief executive officer, as well as a ... to ArmaGen more than 17 years of executive ... of biotherapeutics and pharmaceuticals. "Mathias ... experience and skillset necessary to lead ArmaGen to ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
Breaking Biology News(10 mins):